Addressing specific aetiology and aggressive risk factor modification remain the mainstay in the treatment of heart failure with preserved ejection fraction.
This review highlights that treatment for HFpEF primarily focuses on symptom reduction, morbidity benefits, and risk factor modification, as therapies proven for HFrEF lack clinical support in this population.
Heart failure with preserved ejection fraction (HFPEF) is common and represents a major challenge in cardiovascular medicine. Most of the current treatment of HFPEF is based on morbidity benefits and symptom reduction. Various pharmacological interventions available for heart failure with reduced ejection fraction have not been supported by clinical studies for HFPEF. Addressing the specific aetiology and aggressive risk factor modification remain the mainstay in the treatment of HFPEF. We present a brief overview of the currently recommended therapeutic options with available evidence.
Muhammad Asrar ul Haq (2014) conducted a review in Heart failure with preserved ejection fraction (HFPEF). Therapeutic interventions was evaluated. Addressing specific aetiology and aggressive risk factor modification remain the mainstay in the treatment of heart failure with preserved ejection fraction.